AstraZeneca solar panel field at its Macclesfield location in the UK.

As­traZeneca ad­vances net-ze­ro car­bon goals, adding Hon­ey­well deal and out­sider over­sight among new ESG ef­forts

Just a few years ago, the phar­ma in­dus­try was la­beled as a big-time car­bon pol­luter in a study that showed green­house gas emis­sions that were 55% high­er than the au­to in­dus­try. The study and me­dia re­ports that fol­lowed ex­pressed some shock amid sur­pris­ing­ly scant at­ten­tion paid to the in­dus­try by en­vi­ron­men­tal watch­ers.

Since then, how­ev­er, phar­ma com­pa­nies have tak­en up the chal­lenge — in­clud­ing ef­forts by many to dri­ve to net-ze­ro emis­sion goals. As­traZeneca, along with No­var­tis and Mer­ck, is lead­ing the time race in the in­dus­try, set­ting com­pa­ny goals for 2025, fol­lowed by a larg­er group of phar­mas aim­ing for 2030. ESG track­er SP­Glob­al notes J&J, Pfiz­er, Glax­o­SmithK­line, Sanofi and BioN­Tech among the lat­ter group.

Juli­ette White

For As­traZeneca, the dri­ve to get to ze­ro car­bon emis­sions with­in the next three years is a $1 bil­lion in­vest­ment be­gun in 2020 — and now well on track to hit those tar­gets, ac­cord­ing to its re­cent­ly re­leased an­nu­al sus­tain­abil­i­ty re­port.

By the end of 2021, it had re­duced its green­house gas foot­print by 59% and achieved 100% re­new­able elec­tric­i­ty across its own sites, said Juli­ette White, As­traZeneca’s VP of glob­al safe­ty, health and en­vi­ron­men­tal (SHE) and op­er­a­tions sus­tain­abil­i­ty. As­traZeneca is al­so mak­ing progress with key sup­pli­ers and part­ners, con­firm­ing they’ll have their own sci­ence-based de­car­boniza­tion tar­gets set by 2025.

The lat­est ad­di­tion to its “Am­bi­tion Ze­ro Car­bon” plan is a deal with Hon­ey­well inked in Feb­ru­ary to de­vel­op next-gen in­halers for asth­ma and COPD pa­tients us­ing an en­vi­ron­men­tal­ly friend­ly pro­pel­lant.

As­traZeneca was al­so re­cent­ly named among the first sev­en glob­al com­pa­nies — and on­ly phar­ma — to have its net-ze­ro ef­forts ver­i­fied by the stan­dards group Sci­ence Based Tar­gets ini­tia­tive.

Its en­vi­ron­men­tal goals, along with its two oth­er key ESG pri­or­i­ties around ethics and trans­paren­cy, and ac­cess to health­care “work in con­cert with one an­oth­er,” White said.

To make sure it’s stay­ing on track and ac­count­able, As­traZeneca now in­cludes out­side mem­bers on its ESG over­sight board. It amped its gov­er­nance, the G in ESG, with a new sus­tain­abil­i­ty sub­com­mit­tee that in­cludes four non-ex­ec­u­tive di­rec­tors with over­sight — and in­put on fu­ture ini­tia­tives.

“The board sub­com­mit­tee gives ad­di­tion­al over­sight but al­so demon­strates and un­der­scores the re­al com­mit­ment that we have,” she said, adding that the board al­so helps As­traZeneca “strate­gi­cal­ly stretch in a true full ESG sense and not just the pro­grams around car­bon.”

The over­all ESG ef­forts by As­traZeneca and the en­tire phar­ma in­dus­try mat­ter not on­ly be­cause their cus­tomers — pa­tients and HCPs — but al­so in­vestors, are de­mand­ing it.

“We’ve al­ways seen those tra­di­tion­al ESG in­vestors have a keen in­ter­est, but what we are be­gin­ning to see is a broad­er, per­haps non-tra­di­tion­al in­vestors ask ESG ques­tions, which I think most of us would say we see as a healthy and pos­i­tive move­ment that we’re see­ing so­cial­ly as a whole,” White said.

The Big Phar­ma dis­card pile; Lay­offs all around while some biotechs bid farewell; New Roche CEO as­sem­bles top team; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

With earnings seasons in full swing, we’ve listened in on all the calls so you don’t have to. But news is popping up from all corners, so make sure you check out our other updates, too.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Trodelvy notch­es a win in most com­mon form of breast can­cer

Following a promise last year to go “big and fast in breast cancer,” Gilead has secured a win for Trodelvy in the most common form.

The drug was approved to treat HR-positive, HER2-negative breast cancer patients who’ve already received endocrine-based therapy and at least two other systemic therapies for metastatic cancer, Gilead announced on Friday.

Trodelvy won its first indication in metastatic triple-negative breast cancer back in 2020, and has since added urothelial cancer to the list. HR-positive HER2-negative breast cancer accounts for roughly 70% of new breast cancer cases worldwide per year, according to senior VP of oncology clinical development Bill Grossman, and many patients develop resistance to endocrine-based therapies or worsen on chemotherapy.

Sen. Ron Wyden (D-OR) (Francis Chung/E&E News/Politico via AP Images)

In­fla­tion re­bates in­com­ing: Wyden calls on CMS to move quick­ly as No­var­tis CEO pledges re­ver­sal

Senate Finance Chair Ron Wyden (D-OR) this week sent a letter to the head of the Centers for Medicare & Medicaid Services seeking an update on how and when new inflation-linked rebates will take effect for drugs that see major price spikes.

The newly signed Inflation Reduction Act requires manufacturers to pay a rebate to Medicare when they increase drug prices faster than the rate of inflation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

BeiGene's new website helps direct cancer patients and caregivers to a wide variety of sources for help.

BeiGene re­veals men­tal health and can­cer care gap in study, de­buts dig­i­tal re­sources

One-fourth of cancer patients are living with depression — and another 20% suffer from anxiety. That’s according to new study results from BeiGene, conducted by Cancer Support Community (CSC), about the mental and emotional health of cancer patients.

While the fact that people with cancer are also dealing with depression or anxiety may not be surprising, what is — and was to BeiGene — is that a majority of them aren’t getting support. 60% of respondents said they were not referred to a mental health professional, and even more concerning, two in five who specifically asked for mental health help did not get it. CSC, a nonprofit mental health in cancer advocacy group, surveyed more than 600 US cancer patients.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

One of the paintings from Gilead's latest campaign making AI art to help MBC patients be 'seen and heard.'

Gilead com­bines ar­ti­fi­cial in­tel­li­gence and art to draw at­ten­tion and hope to MBC

What if you could “see” the emotions and feelings of people living with metastatic breast cancer? That’s what Gilead Sciences’ agency VMLY&R Health did last year, using artificial intelligence and sound analytics to turn the interviews of three women living with metastatic triple-negative breast cancer into works of art.

Using the sound waves, a robotic painting device translated their stories of struggle and hope into colors, contours and brush strokes. The result? An art exhibition called “Paintings of Hope” that was first displayed at ESMO in September in Paris, but has since traveled to hospitals and medical conferences in Europe and Spain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Te­va drops out of in­dus­try trade group PhRMA

Following in AbbVie’s footsteps, Teva confirmed on Friday that it’s dropping out of the industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA).

Teva didn’t give a reason for its decision to leave, saying only in a statement to Endpoints News that it annually reviews “effectiveness and value of engagements, consultants and memberships to ensure our investments are properly seated.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Sanofi expects its RSV antibody jointly developed with AstraZeneca will be available next season, executive VP of vaccines Thomas Triomphe announced on the company’s quarterly call.

Beyfortus, also known as nirsevimab, was approved in the EU back in November and is currently under FDA review with an expected decision coming in the third quarter of this year. The news comes as the FDA plans to hold advisory committee meetings over the next couple months to review RSV vaccines from Pfizer and GSK.

Christophe Weber, Takeda CEO (Photographer: Shoko Takayasu/Bloomberg via Getty Images)

Take­da fo­cus­es on ‘di­verse’ pipeline prospects on heels of two ac­qui­si­tions

After a whopping $4 billion asset buy from Nimbus Therapeutics, along with a $400 million deal with Hutchmed for a colorectal cancer drug, Takeda executives touted pipeline optimism on its latest earnings call this week.

That’s because the TYK2 inhibitor for psoriasis Takeda is getting from Nimbus, along with the Hutchmed fruquintinib commercialization outside of China, are just two of what it reports are 10 late-stage development programs of promising candidates.

Regeneron CSO George Yancopoulos (L) and CEO Len Schleifer at a groundbreaking for its new Tarrytown, NY facility, June 2022 (Lev Radin/Pacific Press/LightRocket via Getty Images)

In show­down with Roche, Re­gen­eron gears up for po­ten­tial Eylea ex­pan­sion amid Covid de­cline

Regeneron faced a substantial slump in overall revenue last year, but the focus still remains on some of its biggest blockbusters.

The pharma with several high-profile partnerships — Sanofi and Bayer among them — said Friday that Q4 revenue was down 31% for the quarter, and down 24% for the entire year. However, that won’t stop blockbuster expansion plans.

One of those is Eylea, the Bayer-partnered eye disease drug that has been in major competition with Roche’s Vabysmo. While Eylea is currently only approved in a 2 mg dose, the company recently filed for approval to give a 8 mg dose, in hopes of making a longer-lasting treatment.